These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 11904783)

  • 41. Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia.
    Shaikh AJ; Bawany SA; Masood N; Khan AA; Abbasi AN; Niamutullah SN; Zaidi A; Adil S; Kumar S
    J Cancer; 2011 Jan; 2():62-6. PubMed ID: 21326626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic burden of haematological adverse effects in cancer patients: a systematic review.
    Liou SY; Stephens JM; Carpiuc KT; Feng W; Botteman MF; Hay JW
    Clin Drug Investig; 2007; 27(6):381-96. PubMed ID: 17506589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The economic burden of supportive care of cancer patients.
    Elting LS; Shih YC
    Support Care Cancer; 2004 Apr; 12(4):219-26. PubMed ID: 14767748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study.
    Innes HE; Smith DB; O'Reilly SM; Clark PI; Kelly V; Marshall E
    Br J Cancer; 2003 Jul; 89(1):43-9. PubMed ID: 12838298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outpatient therapy for febrile neutropenia: clinical and economic implications.
    de Lalla F
    Pharmacoeconomics; 2003; 21(6):397-413. PubMed ID: 12678567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
    Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
    Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer.
    Teuffel O; Amir E; Alibhai SM; Beyene J; Sung L
    Pediatrics; 2011 Feb; 127(2):e279-86. PubMed ID: 21220399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices.
    Elting LS; Cantor SB
    Support Care Cancer; 2002 Apr; 10(3):189-96. PubMed ID: 11904783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
    Lyman GH; Kuderer NM
    Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outpatient management of febrile neutropenia: time to revise the present treatment strategy.
    Carstensen M; Sørensen JB
    J Support Oncol; 2008; 6(5):199-208. PubMed ID: 18551855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
    Lyman GH; Kuderer NM
    Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.